Good
Partially Aligned
Patient Risk:
Medium
Summary
Most pregnancy/lactation contraception and animal embryo-fetal toxicity details are consistent with the supplied excerpts. However, multiple contraception timing statements (female 6 months vs label 7 months; male 4 months match; and the label supports contraception for 7 months after last dose, not 6), plus an overbroad/unsupported breastfeeding timing statement and an incorrect characterization of FDA pregnancy category were identified as unsupported or conflicting with the provided labeling excerpts.
Category Scores
Accurate Statements
Lurbinectedin (Zepzelca) is approved for metastatic small cell lung cancer.
Provided label excerpt 1.2: “ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.”
The prescribing information states lurbinectedin can cause fetal harm when administered to pregnant women.
Provided label excerpt 5.5: “Based on animal data and its mechanism of action ZEPZELCA can cause fetal harm when administered to a pregnant woman…”
Embryo-fetal toxicity included post-implantation loss.
Label excerpt supplied does not explicitly mention post-implantation loss; therefore this is not verifiable from the provided excerpts. (This item is included only if the AI statement was supported by provided label text; however no explicit support is present in the supplied excerpts.)
Unsupported Statements
Lurbinectedin is classified as Pregnancy Category D by the FDA.
The supplied label excerpts do not include an FDA pregnancy category designation.
Pregnancy Category D indicates positive evidence of human fetal risk based on animal data and limited human reports, though potential benefits may warrant use in life-threatening situations.
No pregnancy category definition is present in the supplied label excerpts.
In rats and rabbits, lurbinectedin caused embryo-fetal toxicity at doses about 0.4 to 1 times the human clinical exposure.
The supplied excerpts provided do not include specific quantitative animal dosing/exposure ratios.
Embryo-fetal toxicity included decreased fetal weight.
No specific animal findings (e.g., decreased fetal weight) are stated in the provided excerpts.
Embryo-fetal toxicity included malformations such as cleft palate.
No specific malformation types are stated in the provided excerpts.
Embryo-fetal toxicity included skeletal anomalies.
No specific skeletal findings are stated in the provided excerpts.
Rabbits showed higher sensitivity to lurbinectedin.
No comparative species sensitivity statement is included in the provided excerpts.
In rabbits, embryo-fetal toxicity included abortions.
No specific abortion outcome is stated in the provided excerpts.
In rabbits, embryo-fetal toxicity included total litter losses at lower doses.
No specific litter loss/timing/dose details are stated in the provided excerpts.
No adequate controlled studies exist in pregnant women.
The supplied excerpts do not address availability of controlled studies in pregnant women.
The label advises avoiding lurbinectedin use during pregnancy.
The supplied excerpts advise pregnant women of potential risk and contraception timing, but do not explicitly state “avoid use during pregnancy.”
Women of reproductive potential must use effective contraception during lurbinectedin treatment.
Label excerpt 5.5 and 8.3 support contraception during treatment, but contraception timing after last dose is inconsistent (see contradiction). This statement itself is supported.
Women of reproductive potential must use effective contraception for at least 6 months after the final dose of lurbinectedin.
Label excerpt 5.5 and 8.3 state 7 months after the last dose.
Men with female partners should use contraception during lurbinectedin treatment.
Supported by label 5.5/8.3 (during treatment), but no contradiction for this subpart.
Lurbinectedin has a pregnancy exposure registry to track outcomes.
The supplied excerpts do not mention a pregnancy exposure registry.
If lurbinectedin exposure occurs during pregnancy, potential fetal risks include spontaneous abortion.
The supplied excerpts do not list specific risks by term (e.g., spontaneous abortion) for exposed pregnancies.
If lurbinectedin exposure occurs during pregnancy, potential fetal risks include congenital malformations.
The supplied excerpts do not list specific fetal risk categories by term.
If lurbinectedin exposure occurs during pregnancy, potential fetal risks include growth restriction.
The supplied excerpts do not list specific fetal risk categories by term.
Lurbinectedin may pass into breast milk.
The supplied excerpts do not explicitly state that lurbinectedin passes into breast milk.
Breastfeeding is not recommended during lurbinectedin treatment.
Supported by label 8.2 (advise women not to breastfeed during treatment).
Breastfeeding is not recommended for 2 weeks after the final dose of lurbinectedin.
Supported by label 8.2 (“for 2 weeks after the last dose”).
Lurbinectedin may impair male fertility.
The supplied excerpts do not mention fertility impairment for men.
Lurbinectedin may impair female fertility.
The supplied excerpts do not mention fertility impairment for women.
Impairment of fertility with lurbinectedin may be potentially irreversible.
The supplied excerpts do not mention fertility impairment or irreversibility.
Contradictions
Medium
AI Statement
Women of reproductive potential must use effective contraception for at least 6 months after the final dose of lurbinectedin.
Label Reference
Label excerpt 5.5: “use effective contraception during treatment with ZEPZELCA and for 7 months after the last dose.” Also 8.3 repeats 7 months after the last dose.
Important Omissions
For metastatic small cell lung cancer indication, label includes disease progression on/after platinum-based chemotherapy and specifies adult patients and accelerated approval status; the AI statement only said it is approved for metastatic small cell lung cancer.
Importance:
Moderate
Contraception timing for male patients and female patients should match the label precisely (7 months for females; 4 months for males). AI provided an incorrect female duration.
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Primary safety-relevant mismatch is contraception duration after last dose for women (AI: at least 6 months vs label: 7 months). Additional claims (pregnancy registry and specific fetal risks; fertility impairment; pregnancy category) are unsupported by provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Incorrect contraception duration after last dose for women (6 months stated vs 7 months in label excerpts). Several pregnancy/fertility/registry and specific animal risk details are unsupported by the provided excerpts.
Suggested Improvement
Replace the female post-treatment contraception duration with the label value (7 months after the last dose). Remove or qualify unsupported claims not present in the provided excerpts (pregnancy category D definition, pregnancy exposure registry, specific fetal risk terms, and fertility impairment details), or provide the exact label text excerpts that support them.